D
Daniel A. Pollyea
Researcher at University of Colorado Denver
Publications - 253
Citations - 15461
Daniel A. Pollyea is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Myeloid leukemia & Venetoclax. The author has an hindex of 48, co-authored 198 publications receiving 10593 citations. Previous affiliations of Daniel A. Pollyea include University of Colorado Boulder & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D. DiNardo,Keith W. Pratz,Vinod Pullarkat,Brian A. Jonas,Martha Arellano,Pamela S. Becker,Pamela S. Becker,Olga Frankfurt,Marina Konopleva,Andrew H. Wei,Hagop M. Kantarjian,Tu Xu,Wan Jen Hong,Brenda Chyla,Jalaja Potluri,Daniel A. Pollyea,Anthony Letai +16 more
TL;DR: The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML and achieved complete remission (CR) + CR with incomplete count recovery (CRi).
Journal ArticleDOI
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Daniel A. Pollyea,Amir T. Fathi,Gail J. Roboz,Gail J. Roboz,Jessica K. Altman,Richard Stone,Daniel J. DeAngelo,Ross L. Levine,Ian W. Flinn,Hagop M. Kantarjian,Robert H. Collins,Manish R. Patel,Arthur E. Frankel,Anthony S. Stein,Mikkael A. Sekeres,Ronan T. Swords,Bruno C. Medeiros,Christophe Willekens,Christophe Willekens,Paresh Vyas,Alessandra Tosolini,Qiang Xu,Robert Knight,Katharine E. Yen,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Martin S. Tallman,Martin S. Tallman +31 more
TL;DR: Inducing differentiation of myeloblasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib, a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.
Journal ArticleDOI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D. DiNardo,Eytan M. Stein,S. de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Ronan T. Swords,Robert H. Collins,Gabriel N. Mannis,Daniel A. Pollyea,William B. Donnellan,Amir T. Fathi,A. Pigneux,Harry P. Erba,Gabrielle T. Prince,Anthony S. Stein,Geoffrey L. Uy,James M. Foran,Elie Traer,Robert K. Stuart,Martha Arellano,James L. Slack,Mikkael A. Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Martin S. Tallman,Richard Stone,Hagop M. Kantarjian +39 more
TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.
Journal ArticleDOI
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner,Cristina E. Tognon,Cristina E. Tognon,Daniel Bottomly,Beth Wilmot,Stephen E. Kurtz,Samantha L. Savage,Nicola Long,Anna Reister Schultz,Elie Traer,Melissa L. Abel,Anupriya Agarwal,Aurora Blucher,Uma Borate,Jade Bryant,Russell T. Burke,Amy S. Carlos,Richie Carpenter,Joseph Carroll,Bill H. Chang,Cody Coblentz,Amanda d’Almeida,Rachel J. Cook,Alexey V. Danilov,Kim Hien T. Dao,Michie Degnin,Deirdre Devine,James Dibb,David K. Edwards,Christopher A. Eide,Christopher A. Eide,Isabel English,Jason M. Glover,Rachel Henson,Hibery Ho,Abdusebur Jemal,Kara Johnson,Ryan C. Johnson,Brian Junio,Andy Kaempf,Jessica Leonard,Chenwei Lin,Selina Qiuying Liu,Pierrette Lo,Marc M. Loriaux,Samuel B. Luty,Tara A. Macey,Jason D. MacManiman,Jacqueline Martinez,Motomi Mori,Dylan Nelson,Ceilidh Nichols,Jill Peters,Justin Ramsdill,Angela Rofelty,Robert Schuff,Robert P. Searles,Erik Segerdell,Rebecca Smith,Stephen E. Spurgeon,Tyler Sweeney,Aashis Thapa,Corinne Visser,Jake Wagner,Kevin Watanabe-Smith,Kristen Werth,Joelle Wolf,Libbey White,Amy Yates,Haijiao Zhang,Christopher R. Cogle,Robert H. Collins,Denise C. Connolly,Michael W. Deininger,Leylah Drusbosky,Christopher S. Hourigan,Craig T. Jordan,Patricia Kropf,Tara L. Lin,Micaela E. Martinez,Bruno C. Medeiros,Rachel R. Pallapati,Daniel A. Pollyea,Ronan T. Swords,Justin M. Watts,Scott Weir,David L. Wiest,Ryan M. Winters,Shannon K. McWeeney,Brian J. Druker,Brian J. Druker +90 more
TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.
Journal ArticleDOI
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva,Daniel A. Pollyea,Jalaja Potluri,Brenda Chyla,Leah Hogdal,Todd Busman,Evelyn McKeegan,Ahmed Salem,Ming Zhu,Justin L. Ricker,William Blum,Courtney D. DiNardo,Tapan M. Kadia,Martin Dunbar,Rachel Kirby,Nancy Falotico,Joel D. Leverson,Rod A. Humerickhouse,Mack Mabry,Richard Stone,Hagop M. Kantarjian,Anthony Letai +21 more
TL;DR: Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study.